'김갑성' 기자의 전체기사
-
Brightonix Imaging's High-Performance 'PHAROS' PET Receives…
SEOUL, South Korea, Aug. 26, 2025 -- Brightonix Imaging, a global leader in cutting-edge medical imaging technology, is proud to announce that its flagship product, the PHAROS PET Scanner, has received FDA clearance for commercial distribution in the United States. This milestone marks a new era of precision and efficiency in nuclear imaging and positions Brightonix Imaging at the forefront of medical innovation. The PHAROS PET is a state-of-the art clinical positron emission tomography (PET) system designed to deliver exceptional image quality, offering healthcare providers a
- 김갑성 기자
- 2025-08-26 19:00
-
HIRONIC Expands Presence in Indonesian Market with 'New Do…
SEOUL, South Korea, Aug. 26, 2025 -- HIRONIC, a leading provider of aesthetic medical devices, announced on the 19th that it has obtained certification from the Indonesian Ministry of Health (KEMENKES RI) for its flagship product, New Doublo 2.0—a state-of-the-art device combining 4th-generation High-Intensity Focused Ultrasound (HIFU) and Radiofrequency (RF) technologies in a single treatment platform. This approval officially opens the door for exports to one of Southeast Asia's fastest-growing and largest aesthetic markets. With a population of 270 million, Indonesia is the
- 김갑성 기자
- 2025-08-26 15:54
-
하이로닉, '뉴 더블로 2.0' 인도네시아 인증 획득 동남아 시장 공략 가속화
[ 메디채널 김갑성 기자 ] 서울 대한민국 2025년 8월 26일 -- 피부미용 의료기기 전문기업 하이로닉(대표 이진우)이 4세대 하이푸(HIFU)와 고주파(RF) 동시 시술이 가능한 '뉴 더블로 2.0(New Doublo 2.0)'에 대해 인도네시아 보건부(KEMENKES RI) 인증을 획득했다고 19일 밝혔다. 이번 인증으로 하이로닉은 급성장하는 동남아시아 최대 시장인 인도네시아에 '뉴 더블로 2.0'의 공식 수출길을 열며, 현지 시장 공략을 본격화할 예정이다. 인도네시아는 약 2억 7,000만 명에 달하는 동남아시아 최대 인구를 바탕으로 중산층이 빠르게 성장하고 있으며, 이와 함께 미용 및 웰니스 소비가 확대되면서 피부미용 의료기기 시장이 연평균 11.5%의 높은 성장률을 보이고 있다. 특히, 전문 뷰티 클리닉과 병원을 중심으로 고급 시술 수요가 늘어나면서 피부 리프팅, 탄력 개선 등 비침습적 시술과 복합 에너지 기반 시술에 대한 관심이 급증하는 추세다. 뉴 더블로 2.0은 하이푸(고강도 집속초음파), RF(고주파), 그리고 마이크로 니들(Micro Needle) 등 3가지 에너지를 결합한 복합기기로, 하나의
- 김갑성 기자
- 2025-08-26 15:54
-
Abbott receives regulatory approval for the first denosumab…
[ 메디채널 김갑성 기자 ] Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches in Malaysia and India BANGKOK, Aug. 26, 2025 -- Abbott (NYSE: ABT), the global healthcare leader, has received regulatory approval for the first denosumab biosimilar in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone loss. With the introduction of [ 메디채널 김갑
- 김갑성 기자
- 2025-08-26 14:29
-
Basecare Medical (02170.HK) Gems Culture Medium Receives…
SUZHOU, China, Aug. 26, 2025 -- Recently, Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has officially received registration approval from the National Medical Products Administration (NMPA). This marks not only a milestone event in China's assisted reproductive field but also signifies that domestically produced high-end culture media have officially entered the top international tier, completely breaking the monopoly of imported brands that has lasted for over 30 years. VitBase belon
- 김갑성 기자
- 2025-08-26 11:47
-
Fullerton Health Announces Strategic Investment by Mitsubis…
SINGAPORE, Aug. 26, 2025 -- Fullerton Health Pte. Ltd. ("Fullerton Health" or the "Company"), a leading healthcare solutions provider operating in nine markets across Asia-Pacific, today announced that Mitsubishi Corporation has acquired a strategic minority stake in the Company. This partnership marks a significant milestone in Fullerton Health's growth journey, enabling greater shareholder alignment as the Company sharpens its focus on regional growth and accelerates its vision for integrated, digitally enabled care and service. This investme
- 김갑성 기자
- 2025-08-26 10:00
-
MORROW founder invests US $156m and launches new flagsh…
SINGAPORE, Aug. 26, 2025 -- Entrepreneur Allen Law is to open MORROW, a 38,000 sq ft centre that empowers individuals to adopt a healthy lifestyle with a personalised roadmap, supported by a team of professionals and coaches, as part of his global mission to increase the human healthspan. US $156m (SGD $200m) will be invested in opening MORROW locations over the next five years, with US $15.6M (SGD $20m) invested in the initial set-up and technology of an initial flagship in Singapore, which will be located inside the 80,000 sq ft Longevity World at 10 Coleman Street. T
- 김갑성 기자
- 2025-08-26 08:00
-
Angelalign Technology Announces First-Half 2025 Results W…
SAN CLEMENTE, Calif., Aug. 26, 2025 -- Angelalign Technology Inc. ("Angel" or the "Company") (6699.HK) announced its interim results for the first half of 2025. The Company delivered solid performance for the first six months of the year. In the first half of 2025, Angel reported a year-over-year revenue increase of 33.1% to US$161.4 million, with gross profit of US$100.6 million and adjusted net profit of US$19.5 million. Global clear aligner case volume grew 47.7% year-over-year to approximately 225,800 cases. The growth in case shipments, a
- 김갑성 기자
- 2025-08-26 07:28
-
Infinitus Named in Liaowang Institution's "Leading Transpa…
GUANGZHOU, China, Aug. 26, 2025 -- Amid the digital economy and shifting consumer expectations, "trust" has become a core driver of sustainable business growth. The "Transparent Factory • Building the Future with Trust — 2025 Trust Productivity High-End Dialogue" was held in Jiangmen, Guangdong from August 19-20, 2025. During the event, Xinhua News Agency's national high-end think tank, Liaowang Institution, released a report titled "Digital Intelligence Driving • Value Enhancement: Leading Transparent Factory Case Studies" (the "Report"). Infinitus (Ch
- 김갑성 기자
- 2025-08-26 02:55
-
Neopharma Technologies and Orient Gene Partner to Digitiz…
Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 -- Neopharma Technologies Limited ("Neopharma") today announced it has entered into a global software licensing and collaboration agreement with Zhejiang Orient Gene Biotech Co., Ltd. ("Orient Gene") to integrate Neopharma's NEOVAULT® software across Orient Gene's range of Drugs of Abuse (DOA) rapid tests under the Healgen® brand. Why This Matters The partnership combines proven rapid drug tes
- 김갑성 기자
- 2025-08-26 02:10
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025 23:42
- HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet 23:37
- United Imaging Marks Five Years Since the Opening of its Global Showroom In North America with a Record Number of U.S. Customer Visits 22:00
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 20일 01시 20분